Cargando…

Impact of Pre-Transplant Measurable Residual Disease on Outcome of Allogeneic Hematopoietic Cell Transplantation in Adult Monosomal Karyotype AML

Allogeneic hematopoietic cell transplantation (HCT) is often unsuccessful for monosomal karyotype (MK) acute myeloid leukemia (AML). To what degree failures are associated with pre-transplant measurable residual disease (MRD) – a dominant adverse risk factor – is unknown. We therefore studied 606 ad...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morsink, Linde M., Othus, Megan, Bezerra, Evandro D., Wood, Brent L., Fang, Min, Sandmaier, Brenda M., Mielcarek, Marco, Schoch, Gary, Storb, Rainer, Joachim Deeg, H., Appelbaum, Frederick R., Walter, Roland B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7272254/ https://www.ncbi.nlm.nih.gov/pubmed/31974434 http://dx.doi.org/10.1038/s41375-020-0717-0

Ejemplares similares

Conditioning Intensity, Pre-Transplant Flow Cytometric Measurable Residual Disease, and Outcome in Adults with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation
por: Morsink, Linde M., et al.
Publicado: (2020)

Utility of Treatment-Related Mortality (TRM) Score to Predict Outcomes of Adults with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation
por: Zarling, Lucas C., et al.
Publicado: (2022)

Contribution of measurable residual disease status to prediction accuracy of relapse and survival in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation
por: Rodríguez-Arbolí, Eduardo, et al.
Publicado: (2022)

Association between Prior Cytotoxic Therapy, Antecedent Hematologic Disorder, and Outcome after Allogeneic Hematopoietic Cell Transplantation in Adult Acute Myeloid Leukemia
por: Orvain, Corentin, et al.
Publicado: (2023)

Comparison of Minimal Residual Disease as Outcome Predictor for AML Patients in First Complete Remission Undergoing Myeloablative or Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation
por: Walter, Roland B., et al.
Publicado: (2014)

Impact of induction regimen and allogeneic hematopoietic cell transplantation on outcome in younger adults with acute myeloid leukemia with a monosomal karyotype
por: Baron, Frédéric, et al.
Publicado: (2019)

Prognostic factors and outcomes of severe gastrointestinal graft-vs.-host disease after allogeneic hematopoietic cell transplantation
por: Castilla-Llorente, Cristina, et al.
Publicado: (2014)

Relative impact of residual cytogenetic abnormalities and flow cytometric measurable residual disease on outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia
por: Orvain, Corentin, et al.
Publicado: (2022)

Genotype-outcome correlations in pediatric AML: the impact of a monosomal karyotype in trial AML-BFM 2004
por: Rasche, M, et al.
Publicado: (2017)

Allogeneic Hematopoietic Cell Transplantation in Patients with Myelodysplastic Syndrome and Concurrent Lymphoid Malignancy
por: Zimmerman, Zachary, et al.
Publicado: (2011)

Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma
por: Maffini, Enrico, et al.
Publicado: (2019)

Analysis of Antibiotic Exposure and Development of Acute Graft-vs-Host Disease Following Allogeneic Hematopoietic Cell Transplantation
por: Rashidi, Armin, et al.
Publicado: (2023)

Monosomal karyotype in myeloid neoplasias: a literature review
por: Anelli, Luisa, et al.
Publicado: (2017)

The Elephant in The Room: AML Relapse Post Allogeneic Hematopoietic Cell Transplantation
por: Abou Dalle, Iman, et al.
Publicado: (2022)

Monosomal karyotype in Philadelphia chromosome-negative acute lymphoblastic leukemia
por: Kenderian, S S, et al.
Publicado: (2013)

Poor Prognosis in Acute Myeloid Leukemia Patients with Monosomal Karyotypes
por: Xu, Junqing, et al.
Publicado: (2017)

Role of Comorbidities in Optimizing Decision-Making for Allogeneic Hematopoietic Cell Transplantation
por: Sorror, Mohamed L., et al.
Publicado: (2010)

Extracorporeal Photopheresis in Addition to Pentostatin in Conditioning for Canine Hematopoietic Cell Transplantation: Role in Engraftment
por: Bethge, Wolfgang A., et al.
Publicado: (2010)

Extracorporeal photopheresis combined with pentostatin in the conditioning regimen for canine hematopoietic cell transplantation does not prevent GVHD
por: Bethge, Wolfgang, et al.
Publicado: (2014)

Editorial: The Elephant in the Room: AML Relapse After Allogeneic Hematopoietic Cell Transplantation
por: Battipaglia, Giorgia, et al.
Publicado: (2022)

Generalist in allogeneic hematopoietic stem cell transplantation for MDS or AML: Epigenetic therapy
por: Yang, Guancui, et al.
Publicado: (2022)

Not all patients with AML over 60 years of age should be offered early allogeneic stem cell transplantation
por: Deeg, H. Joachim
Publicado: (2022)

Effects of T-Cell Depletion on Allogeneic Hematopoietic Stem Cell Transplantation Outcomes in AML Patients
por: Hobbs, Gabriela Soriano, et al.
Publicado: (2015)

Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: improved outcomes over two decades
por: Cooper, Jason P., et al.
Publicado: (2020)

cGMP production of astatine-211-labeled anti-CD45 antibodies for use in allogeneic hematopoietic cell transplantation for treatment of advanced hematopoietic malignancies
por: Li, Yawen, et al.
Publicado: (2018)

A diffuse rash in a patient after allogeneic hematopoietic stem cell transplant for AML
por: Ferdjallah, Asmaa, et al.
Publicado: (2020)

Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation
por: Joshi, Maansi, et al.
Publicado: (2021)

Total body irradiation dose escalation decreases risk of progression and graft rejection after hematopoietic cell transplantation for myelodysplastic syndromes or myeloproliferative neoplasms
por: Monaco, Federico, et al.
Publicado: (2019)

What Role Is There for Antithymocyte Globulin in Allogeneic Nonmyeloablative Canine Hematopoietic Cell Transplantation?
por: Diaconescu, Razvan, et al.
Publicado: (2005)

Reconstitution of T Cell Subsets Following Allogeneic Hematopoietic Cell Transplantation
por: Dekker, Linde, et al.
Publicado: (2020)

The Quality of Life of Adult Survivors of Childhood Hematopoietic Cell Transplant
por: Sanders, Jean E., et al.
Publicado: (2009)

P1282: MOCRAVIMOD IMPROVES OVERALL SURVIVAL IN AML PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
por: Medinger, Michael, et al.
Publicado: (2023)

MRD as Biomarker for Response to Donor Lymphocyte Infusion after Allogeneic Hematopoietic Cell Transplantation in Patients with AML
por: Teich, Katrin, et al.
Publicado: (2023)

Addition of venetoclax to myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in high-risk AML
por: Cao, Xing-yu, et al.
Publicado: (2023)

Bridging Strategies to Allogeneic Transplant for Older AML Patients
por: Hecker, Judith, et al.
Publicado: (2018)

Results of a phase 1 study of quizartinib as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic stem cell transplant
por: Sandmaier, Brenda M., et al.
Publicado: (2017)

Allogeneic hematopoietic cell transplant for normal karyotype acute myeloid leukemia: Indirect evidence of selection for adverse molecular profile
por: Percival, Mary-Elizabeth M., et al.
Publicado: (2015)

History of hematopoietic cell transplantation: challenges and progress
por: Granot, Noa, et al.
Publicado: (2020)

Graft Immune Cell Composition Associates with Clinical Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with AML
por: Impola, Ulla, et al.
Publicado: (2016)

Single monosomy as a relatively better survival factor in acute myeloid leukemia patients with monosomal karyotype
por: Jang, J E, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_a1vi1nutpkhi2nas83lhrmiaqr